ArticleCureus2026
Radiological Presentations of Prostatic Carcinoma Patients: A Retrospective Observational Study From a Tertiary Care Oncology Setup.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction Prostate cancer is the second most common cancer in men. Accurate staging is necessary for optimal planning before treatment. Radiological imaging has a significant role in the evaluation of tumor detection, lymph node involvement, and distant metastasis. Despite the advancements in diagnostic radiological imaging, there is still insufficient local data addressing the radiological spectrum of prostate cancer presentations and their link to clinical and pathological factors. Methodology A retrospective cross-sectional analysis was performed at the Shaukat Khanum Memorial Cancer Hospital and Research Centre, Lahore, Pakistan. The study included histopathologically confirmed prostate cancer cases presenting between January 2015 and December 2019. Computed tomography (CT) and magnetic resonance imaging (MRI) findings were reviewed. TNM staging, prostate-specific antigen (PSA) levels, and Gleason scores were recorded. Data analysis was conducted using SPSS version 26 (IBM Inc., Armonk, New York), utilizing univariate and multivariate regression to determine the associations between demographic and clinical variables with metastasis and lymph node involvement. Results Only 203 patients were included, with a mean age of 65.13 ± 6.84 years. The majority of the participants were >65 years old (117; 57.6%), PSA level of 4-10 ng/ml (258; 77.8%), and Gleason score of 8-10 (121; 59.6%). The most common radiological stage was T3b (104; 51.2%). Metastasis and lymph node involvement were present in 120 (59.1%) and 87 (42.9%), respectively. Bones (97; 47.8%) were the predominant site of primary metastasis. PSA level 10ng/ml and high Gleason score had a significant association with metastasis. Conclusion Most patients presented with advanced-stage prostate cancer, lymph node involvement, and metastases. Elevated PSA levels and high Gleason scores were significantly associated with the presence of metastasis. These findings highlight the necessity for earlier detection through enhanced awareness and screening of prostate cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.